Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
Go back to Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes| AGIOS PHARM (NASDAQ: AGIO) | Delayed: 34.16 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.16 | 52 Week High | $71.49 | |||
| Open | $34.16 | 52 Week Low | $33.50 | |||
| Day High | $34.16 | P/E | N/A | |||
| Day Low | $34.16 | EPS | $-1.18 | |||
| Volume | 132 | |||||
